Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment - 23/07/20
Doi : 10.1016/j.amjmed.2020.01.016
Milton Packer, MD a, b, ⁎ 
a Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Tex
b Imperial College, London, UK
⁎Requests for reprints should be addressed to Milton Packer, MD, Baylor Heart and Vascular Institute, 621 N. Hall Street, Dallas, TX 75226.Baylor Heart and Vascular Institute621 N. Hall StreetDallasTX75226
Le texte complet de cet article est disponible en PDF.
| Funding: None. |
|
| Conflicts of Interest: MP served as a consultant for Abbvie, Actavis, Akcea, Amgen, AstraZeneca, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Johnson & Johnson, NovoNordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics and Theravance. |
|
| Authorship: The author is solely responsible for the content of this manuscript. |
© 2020
Elsevier Inc. Tous droits réservés.
Vol 133 - N° 7
P. 781-782 - juillet 2020 Retour au numéro
Article précédent
- Five Questions Every Mentee Should Have an Answer To
- Sanjay Saint, Vineet Chopra
- Multiple Sclerosis and Smoking
- Borros Arneth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?